CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for phlebotomy among polycythemia vera patients who had been dependent on it, the ...

ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in phlebotomy requirements through 52 weeks in patients with polycythemia vera (PV), ...

Please provide your email address to receive an email when new articles are posted on . Rusfertide reduced need for phlebotomies and offered better hematocrit control than placebo. Results showed ...

NEWARK, CA / ACCESSWIRE / March 15, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company"), today announced positive topline results from the blinded, placebo-controlled, ...

PARKVILLE, Mo.--(BUSINESS WIRE)--Bond Biosciences (“Bond” or “the Company”) announced positive clinical results today from its 24-person Phase 1a/b, randomized, double-blind, placebo-controlled, ...

Rusfertide demonstrated favorable safety, tolerability, and therapeutic effect, decreasing and normalizing average TSAT and iron levels and reducing phlebotomy frequency during the 24-week study Data ...

Rusfertide may eliminate therapeutic phlebotomies in polycythemia vera, showing symptomatic improvement and potential treatment utility. Besremi outperformed anagrelide in essential thrombocythemia, ...

US FDA accepts Takeda and Protagonist’s NDA and grants priority review status for rusfertide as a potential first-in-class therapy for polycythaemia vera: Osaka Wednesday, March ...

Nuvisertib received FDA fast track designation for myelofibrosis, showing significant clinical activity in symptom and spleen response, and improvements in bone marrow fibrosis, hemoglobin, and ...